BIMZELX Drug Profile

Summary for Tradename: BIMZELX

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for BIMZELX
Recent Clinical Trials:	See clinical trials for BIMZELX

See drug prices for BIMZELX

Recent Clinical Trials for BIMZELX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
UCB Biopharma SRL	PHASE1

See all BIMZELX clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BIMZELX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BIMZELX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for BIMZELX Derived from Patent Text Search

No patents found based on company disclosures

BIMZELX Market Dynamics, Financial Trajectory, Patent Exposure, and Competitive Outlook

Last updated: October 1, 2026

BIMZELX, UCB’s bimekizumab, is an IL-17A and IL-17F inhibitor positioned against established biologics in psoriasis and inflammatory arthritis. Its commercial case rests on differentiated dual cytokine blockade, expansion beyond plaque psoriasis, and UCB’s ability to convert strong European uptake into a larger U.S. revenue base. UCB has identified BIMZELX as a multi-billion-euro growth product, with peak sales potential above €4 billion. Near-term growth is supported by indication expansion and physician switching; long-term risks include intense IL-17 competition, payer controls, safety monitoring, and eventual biologic patent challenges.

What is BIMZELX and how does it work?

BIMZELX is the brand name for bimekizumab, a humanized monoclonal antibody that selectively inhibits interleukin-17A and interleukin-17F. It is administered by subcutaneous injection.

The drug’s dual mechanism distinguishes it from several competing IL-17 products:

Product	Active ingredient	Primary cytokine target	Company
BIMZELX	Bimekizumab	IL-17A and IL-17F	UCB
Cosentyx	Secukinumab	IL-17A	Novartis
Taltz	Ixekizumab	IL-17A	Eli Lilly
Siliq	Brodalumab	IL-17 receptor A	Bausch Health
Tremfya	Guselkumab	IL-23	Johnson & Johnson
Skyrizi	Risankizumab	IL-23	AbbVie
Stelara	Ustekinumab	IL-12 and IL-23	Johnson & Johnson

In plaque psoriasis trials, bimekizumab produced high rates of complete or near-complete skin clearance. The commercial proposition is strongest in patients who prioritize rapid, durable skin clearance and in those who have failed or are switching from other biologic classes.

What FDA indications does BIMZELX have?

The FDA initially approved BIMZELX in October 2023 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.[1]

In September 2024, the FDA expanded BIMZELX into active psoriatic arthritis, non-radiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis, now termed radiographic axial spondyloarthritis.[2]

The U.S. indication sequence is commercially important:

Date	FDA milestone	Commercial effect
October 2023	Plaque psoriasis approval	Established U.S. launch platform
November 2023	U.S. commercial launch	Opened access to the largest biologics market
September 2024	Psoriatic arthritis and axial spondyloarthritis approvals	Expanded addressable population and prescriber reach
2024 onward	Continued lifecycle development	Supports wider use across immune-mediated diseases

BIMZELX had already secured broader European authorization before its U.S. launch. The European approvals gave UCB more time to build physician experience, payer coverage, and real-world evidence.

How large is the BIMZELX market opportunity?

BIMZELX competes in large biologic markets rather than a narrow orphan segment. The principal commercial pools are plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.

Plaque psoriasis is the initial revenue engine. It is a mature but expanding biologics market with high treatment persistence and frequent switching among TNF, IL-17, IL-23, and IL-12/23 agents. The leading products have achieved multi-billion-dollar annual sales, creating a substantial opportunity for a differentiated entrant.

Psoriatic arthritis broadens the addressable market because treatment decisions are influenced by joint symptoms, skin disease, enthesitis, dactylitis, and axial disease. Bimekizumab’s dual IL-17A/IL-17F mechanism is particularly relevant where both skin and musculoskeletal outcomes matter.

Axial spondyloarthritis creates a third commercial channel. The market is smaller than psoriasis but has substantial unmet need, particularly among patients who cycle through TNF or IL-17 therapies.

Market drivers

The main factors supporting BIMZELX demand are:

High skin-clearance efficacy in plaque psoriasis.
Availability across dermatology and rheumatology.
Product differentiation through dual IL-17A/F inhibition.
Expansion into psoriatic arthritis and axial spondyloarthritis.
Continued switching from older TNF and IL-12/23 products.
U.S. launch scale and increased payer access.
Potential future expansion into hidradenitis suppurativa and other inflammatory diseases.

Market constraints

The product also faces structural limitations:

Dermatology formularies often favor established IL-23 agents.
Payers can impose step edits and preferred-product restrictions.
IL-17 inhibitors carry class-related candidiasis and inflammatory bowel disease warnings.
UCB lacks the commercial scale of AbbVie, Johnson & Johnson, Novartis, and Eli Lilly.
U.S. gross-to-net discounts can rise as the product seeks broader formulary placement.
Prescribers may prefer IL-23 agents because of dosing convenience and durable efficacy.

What is the financial trajectory for BIMZELX?

BIMZELX is UCB’s principal growth asset. Its sales trajectory moved from pre-commercial launch revenue to several hundred million euros in annual sales within its first full commercial period.

Period	Financial position	Interpretation
2023	Early launch revenue	European sales plus initial U.S. launch activity
2024	Approximately €0.5 billion in annual sales, based on UCB reporting	Rapid international expansion and U.S. ramp
2025 onward	Expansion across psoriasis, psoriatic arthritis, and axial spondyloarthritis	Larger prescriber base and additional treatment settings
Long term	UCB target of more than €4 billion in peak sales	Requires sustained share gains and successful lifecycle execution

UCB’s public financial communications have identified BIMZELX as a product with peak sales potential above €4 billion.[3] That target places the medicine in the same strategic category as the company’s largest growth assets and substantially above the revenue level implied by its initial psoriasis launch.

The financial trajectory depends on four conversion steps:

Converting clinical efficacy into new-patient prescriptions.
Converting prescriptions into durable treatment persistence.
Expanding from dermatology into rheumatology.
Increasing the share of patients switching from competing biologics.

The first step has progressed rapidly in Europe and the United States. The second remains critical because biologic revenue is driven by persistence, refill frequency, and net price rather than prescription volume alone.

How does BIMZELX compare with competing biologics?

BIMZELX versus Cosentyx and Taltz

Cosentyx and Taltz have longer commercial histories, broader physician familiarity, and established payer contracts. BIMZELX competes by offering dual IL-17A/F blockade and strong psoriasis efficacy.

The competitive issue is not whether BIMZELX can enter the IL-17 market. It has done so. The issue is whether its efficacy advantage is large enough to overcome switching friction, payer preferences, and the established distribution infrastructure of Novartis and Eli Lilly.

BIMZELX versus Skyrizi and Tremfya

IL-23 inhibitors have become major competitors in psoriasis because of strong efficacy, convenient dosing, and favorable treatment persistence. Skyrizi and Tremfya are particularly important threats in biologic-naive patients and in patients seeking infrequent administration.

BIMZELX has a stronger positioning where rapid clearance or joint and skin control is central. IL-23 products may retain an advantage where dosing frequency, long-term tolerability, or dermatologist familiarity dominates the decision.

BIMZELX versus Stelara

Stelara has historically benefited from broad indications, extensive physician use, and a mature safety database. Its commercial position has weakened as biosimilar and patent pressures increase. Stelara’s decline creates switching opportunities for BIMZELX, although competing IL-23 agents are also positioned to capture that volume.

What is the Orange Book status of BIMZELX?

BIMZELX is a biologic, so its principal U.S. patent and exclusivity framework is different from that of a conventional small-molecule drug.

The FDA Orange Book primarily lists approved drug products and patent information for small-molecule products. Biologic exclusivity and biosimilar reference-product information are handled through the FDA Purple Book and the Biologics Price Competition and Innovation Act framework.[4]

Key implications include:

Generic substitution under an Abbreviated New Drug Application is not the normal pathway.
A biosimilar sponsor would use a 351(k) application.
Interchangeability is a separate FDA designation.
Patent disputes may proceed under the BPCIA patent-exchange and litigation framework.
Patent information may be disclosed through FDA biologic records, regulatory filings, court actions, and UCB intellectual-property publications rather than through a conventional Orange Book listing.

There is no conventional small-molecule Paragraph IV pathway for BIMZELX. A competitor cannot launch a traditional generic by certifying that an Orange Book-listed patent is invalid or non-infringed.

When does BIMZELX lose exclusivity?

BIMZELX’s U.S. reference-product exclusivity under the BPCIA is generally measured from the date of first licensure. The statute provides 12 years of reference-product exclusivity, subject to FDA interpretation and product-specific regulatory history.[5]

Because the first U.S. approval occurred in October 2023, the statutory reference-product exclusivity period would extend into approximately 2035, although biosimilar approval, patent litigation, and launch timing depend on the full regulatory and patent record.

The practical loss-of-exclusivity date may occur later than the end of regulatory exclusivity if UCB secures enforceable patents covering:

The bimekizumab antibody sequence.
Binding epitopes and functional characteristics.
Manufacturing and cell-line processes.
Formulation and stability.
Dosing regimens.
Specific methods of treating psoriasis or inflammatory arthritis.
Subcutaneous delivery and container systems.

A biosimilar company may file an application before core patent expiration and litigate during the remaining patent term. The earliest commercial entry date therefore depends on patent settlements, court decisions, regulatory approval, and any pediatric or other exclusivity extensions.

What patents protect BIMZELX?

The BIMZELX patent estate is expected to include U.S., European, and international families covering the antibody, production methods, pharmaceutical compositions, and clinical use.

The most commercially important patent categories are:

Patent category	Strategic value
Composition of matter	Usually the strongest barrier to biosimilar entry
Antibody sequence and binding site	Protects the molecule and related variants
Manufacturing process	Can complicate development and comparability
Formulation	May protect concentration, stability, and storage characteristics
Dosing regimen	Supports lifecycle management and label-specific protection
Method of treatment	Can preserve selected indications after composition claims expire
Delivery device	May protect prefilled syringes or autoinjectors

Composition patents are generally more valuable than narrow method-of-use claims because a biosimilar sponsor may design around a specific indication while still seeking approval for the molecule. Manufacturing patents can create additional technical barriers but are harder to assess without detailed process disclosure and litigation history.

UCB’s patent strength is therefore best assessed as a layered estate rather than by a single expiration date. The commercial defense is strongest while composition, formulation, and regulatory exclusivity overlap.

Which companies are challenging BIMZELX?

No major U.S. BIMZELX biosimilar challenge had produced a publicly established commercial launch pathway as of the available regulatory and company disclosures. The likely future challengers are large biosimilar manufacturers with experience in monoclonal antibodies, including:

Samsung Bioepis
Celltrion
Sandoz
Amgen
Biocon Biologics
Fresenius Kabi
Pfizer

A biosimilar program would require analytical similarity, pharmacokinetic and immunogenicity data, manufacturing capacity, and a commercial strategy that can withstand payer contracting. Because BIMZELX is still in its early commercial lifecycle, biosimilar developers have limited economic incentive to incur substantial development costs before the market reaches greater maturity.

What patent litigation affects BIMZELX?

The principal litigation risk is future BPCIA litigation rather than current generic litigation. The likely dispute areas are:

Whether a proposed biosimilar infringes composition claims.
Whether UCB’s antibody claims are valid over prior art.
Whether formulation or manufacturing claims are enforceable.
Whether a biosimilar can launch for non-patented indications.
Whether settlement terms impose a delayed-entry date.
Whether the biosimilar is designated interchangeable.

There was no disclosed major U.S. Paragraph IV litigation comparable to small-molecule generic disputes in the early BIMZELX commercial period. A later patent case could still materially affect the product’s loss-of-exclusivity date.

Does BIMZELX have biosimilar risk?

Biosimilar risk is low in the near term and increases materially after the mid-2030s. The risk profile has three stages:

Period	Biosimilar risk	Main issue
2024-2030	Low	Early lifecycle and limited economic incentive
2030-2035	Moderate	Development programs and patent challenges may emerge
After approximately 2035	High	Reference-product exclusivity and selected patents may expire

Biosimilar erosion is likely to be slower than small-molecule generic erosion because biologics require physician confidence, payer contracting, manufacturing capacity, and patient switching. A successful interchangeable biosimilar could accelerate price pressure, particularly in government and managed-care channels.

What licensing deals support BIMZELX?

BIMZELX is primarily a UCB-developed and UCB-commercialized product. Its commercial profile is different from products built around a large external co-promotion partnership.

UCB’s control of development, regulatory strategy, and commercialization gives it a greater share of product economics but also leaves the company responsible for launch execution, market access, manufacturing, and post-approval studies. The absence of a major global commercialization partner increases strategic control but places more pressure on UCB’s sales force and regional infrastructure.

How strong is the BIMZELX patent estate?

The estate is commercially strong during the first decade after U.S. approval because regulatory exclusivity, core biologic patents, and multiple secondary patent categories overlap. Its long-term strength depends on whether UCB can defend composition claims and maintain meaningful protection around formulation, manufacturing, and dosing.

A qualitative assessment is:

Factor	Assessment
Regulatory exclusivity	Strong
Near-term biosimilar threat	Low
Composition protection	Strategically critical
Formulation protection	Potentially meaningful
Method-of-use protection	Useful but narrower
Manufacturing barriers	Moderate to strong
Litigation exposure	Likely to increase later in lifecycle
Global coverage	Broad, reflecting major-market approvals

What generic launch scenarios exist for BIMZELX?

The most plausible launch scenarios are:

Delayed biosimilar entry after negotiated settlement

UCB could settle with one or more biosimilar developers for a specified entry date. This would preserve revenue through the settlement period while creating a predictable erosion curve.

Limited indication launch

A biosimilar sponsor may initially seek approval for indications not covered by enforceable method-of-use patents. This could create partial competition before complete label coverage expires.

Interchangeable biosimilar launch

An interchangeable product could create stronger substitution pressure, especially in payer-controlled channels. The effect would depend on state substitution rules, formulary design, and contracting.

Multiple biosimilar entrants

Several entrants could produce faster price erosion. This scenario becomes more likely if BIMZELX reaches multi-billion-euro sales and supports a large enough market to justify parallel development programs.

What is the revenue exposure for UCB?

BIMZELX is increasingly important to UCB’s growth profile. A product that reaches €4 billion or more in peak sales would represent a substantial share of the company’s revenue and operating profit.

That concentration creates both upside and risk:

Strong launch execution can accelerate UCB’s growth rate.
Slower U.S. uptake would affect company guidance.
Payer discounting can reduce net sales even if volume expands.
Safety signals could affect multiple indications simultaneously.
A successful biosimilar could create a larger absolute revenue loss because of the product’s scale.
Expansion into rheumatology reduces dependence on psoriasis but increases execution complexity.

UCB’s other growth products, including Fintepla and Rystiggo, provide diversification, but BIMZELX remains central to the company’s medium-term financial narrative.[3]

Key Takeaways

BIMZELX is UCB’s dual IL-17A/F biologic for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
U.S. approval began in October 2023, followed by major rheumatology expansions in September 2024.
Revenue reached roughly €0.5 billion in 2024 based on UCB’s reported commercial trajectory.
UCB has stated peak-sales potential above €4 billion.
The main commercial competitors are Skyrizi, Tremfya, Cosentyx, Taltz, Stelara, and other biologics.
Near-term biosimilar risk is low because of the product’s early lifecycle and biologic development requirements.
The relevant U.S. framework is the Purple Book and BPCIA, not a conventional Orange Book Paragraph IV process.
Core composition, formulation, manufacturing, dosing, and method-of-use patents are expected to create layered protection.
Long-term value depends on U.S. market access, rheumatology adoption, treatment persistence, and defense against IL-23 competitors.
UCB’s peak-sales target makes BIMZELX a major driver of corporate revenue, earnings growth, and future patent exposure.

FAQs

How often is BIMZELX administered?

The dosing schedule depends on the indication and treatment phase. Plaque psoriasis typically uses loading doses followed by maintenance injections. The exact schedule is determined by the FDA-approved prescribing information.

Does BIMZELX work better than Skyrizi?

Head-to-head efficacy comparisons are indication-specific. BIMZELX has demonstrated high skin-clearance rates, while Skyrizi has strong efficacy, durable persistence, and less frequent maintenance dosing. Product choice depends on clinical priorities, payer access, safety considerations, and physician judgment.

Is BIMZELX covered by Medicare?

Coverage depends on the Medicare Part D plan, formulary tier, prior-authorization criteria, and the indication. Medicare coverage can differ materially from commercial insurance coverage.

Can BIMZELX be used for inflammatory bowel disease?

BIMZELX is not broadly positioned as an inflammatory bowel disease treatment. IL-17 pathway inhibition can be associated with worsening or new inflammatory bowel disease, making the approved label and patient history important in treatment selection.

What would most weaken UCB’s BIMZELX forecast?

The largest risks are slower U.S. adoption, stronger-than-expected IL-23 competition, payer exclusion, safety-related restrictions, weak persistence, and a patent settlement that permits earlier biosimilar entry.

References

U.S. Food and Drug Administration. (2023, October 17). FDA approves new treatment for moderate-to-severe plaque psoriasis. https://www.fda.gov/
U.S. Food and Drug Administration. (2024, September 23). FDA approves bimekizumab-bkzx for active psoriatic arthritis and axial spondyloarthritis. https://www.fda.gov/
UCB. (2024). Annual report 2024 and financial results. UCB S.A. https://www.ucb.com/
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.

More… ↓

⤷ Start Trial